RA
RARE
HealthcareUltragenyx Pharmaceutical Inc.
Biotechnology
Total Trades
3
Unique Traders
1
Purchases / Sales
3/0
News Articles
5
Trading History
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Feb 18, 2026 |  Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $20.45 | $20.42 | -0.1% | +3.7% | |
Aug 8, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $27.54 | $31.82 | +15.5% | +14.0% | |
Jul 15, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $27.20 | $29.01 | +6.7% | +3.0% |
Recent News
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
Yahoo-Invalid Date
Ultragenyx to Participate at Investor Conferences in March
Yahoo-Invalid Date
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Yahoo-Invalid Date
FDA Accepts Priority Review Of Biologics License Application For ltragenyx Pharmaceutical's DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia
Benzinga-Invalid Date
PTC Therapeutics: Sephience As A Major Growth Driver
SeekingAlpha-Invalid Date